Virtus ETF Advisers LLC Has $300,000 Stake in Sangamo Therapeutics Inc (SGMO)

Virtus ETF Advisers LLC lessened its position in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 13.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 26,120 shares of the biopharmaceutical company’s stock after selling 4,015 shares during the period. Virtus ETF Advisers LLC’s holdings in Sangamo Therapeutics were worth $300,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of SGMO. Wasatch Advisors Inc. raised its position in shares of Sangamo Therapeutics by 12.0% in the third quarter. Wasatch Advisors Inc. now owns 4,544,596 shares of the biopharmaceutical company’s stock valued at $77,031,000 after buying an additional 486,429 shares during the last quarter. Credit Suisse AG raised its position in shares of Sangamo Therapeutics by 23.5% in the third quarter. Credit Suisse AG now owns 2,184,505 shares of the biopharmaceutical company’s stock valued at $37,027,000 after buying an additional 415,764 shares during the last quarter. Tocqueville Asset Management L.P. raised its position in shares of Sangamo Therapeutics by 108.6% in the third quarter. Tocqueville Asset Management L.P. now owns 711,237 shares of the biopharmaceutical company’s stock valued at $12,055,000 after buying an additional 370,297 shares during the last quarter. Capital Fund Management S.A. acquired a new position in shares of Sangamo Therapeutics in the third quarter valued at approximately $4,637,000. Finally, BlackRock Inc. raised its position in shares of Sangamo Therapeutics by 3.0% in the third quarter. BlackRock Inc. now owns 8,322,311 shares of the biopharmaceutical company’s stock valued at $141,063,000 after buying an additional 239,190 shares during the last quarter. 62.27% of the stock is owned by institutional investors and hedge funds.

SGMO traded up $0.01 during trading on Wednesday, hitting $8.96. 29,199 shares of the company’s stock were exchanged, compared to its average volume of 2,474,190. The company has a quick ratio of 6.32, a current ratio of 6.32 and a debt-to-equity ratio of 0.07. Sangamo Therapeutics Inc has a 1 year low of $6.26 and a 1 year high of $27.50. The company has a market cap of $917.82 million, a P/E ratio of -12.84 and a beta of 2.84.

In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $11.49, for a total transaction of $57,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 25,000 shares of company stock valued at $281,500. 1.20% of the stock is owned by insiders.

A number of equities analysts have recently weighed in on SGMO shares. BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Guggenheim lowered shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price target for the company. in a research report on Friday, November 9th. ValuEngine lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Monday, November 19th. Finally, Zacks Investment Research lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 18th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $18.83.

TRADEMARK VIOLATION NOTICE: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.com-unik.info/2019/02/13/virtus-etf-advisers-llc-has-300000-stake-in-sangamo-therapeutics-inc-sgmo.html.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Read More: Why is the conference call important?

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit